Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Nephrology
•
Glomerulonephritis
How do you approach distinguishing between primary and secondary FSGS in a patient who is PLA2R negative?
Related Questions
How do you address patient concerns regarding the necessity of REMS monitoring when prescribing sparsentan?
How do you manage oral prednisone when initiating nefecon in a patient with IgA nephropathy?
What clinical criteria do you use to decide between antivirals, rituximab, plasmapheresis, or a combination therapy for treating hepatitis C virus-associated cryoglobulinemic membranoproliferative glomerulonephritis?
What is your treatment approach for pregnant patients with IgA nephropathy who have worsening proteinuria during the first trimester?
How does your approach to the differential diagnosis of membranous nephropathy change when PLA2R positivity is detected alongside a chronic viral infection such as HIV, HBV, or HCV?
What is your recommended sequence of therapies for achieving optimal proteinuria reduction in IgA nephropathy, especially in light of the recent approvals of sparsentan, delayed-release budesonide, and iptacopan?
How would you tailor immunosuppression in an elderly patient presenting with primary FSGS?
Do you use delayed-release budesonide over prednisone or methylprednisolone for the treatment of IgA nephropathy, considering the available safety and efficacy data?
Would you consider using a combination regimen of rituximab, low-dose cyclophosphamide, and steroids to improve complete remission rates in patient with PLA2R-positive membranous nephropathy?
Do you modify the albumin level below which you would prophylactically anticoagulate a pregnant patient with nephrotic-range proteinuria, given that hypoalbuminemia is expected in pregnancy?
